HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacological Characterization of a Betaine/GABA Transporter 1 (BGT1) Inhibitor Displaying an Unusual Biphasic Inhibition Profile and Anti-seizure Effects.

Abstract
Focal epileptic seizures can in some patients be managed by inhibiting γ-aminobutyric acid (GABA) uptake via the GABA transporter 1 (GAT1) using tiagabine (Gabitril®). Synergistic anti-seizure effects achieved by inhibition of both GAT1 and the betaine/GABA transporter (BGT1) by tiagabine and EF1502, compared to tiagabine alone, suggest BGT1 as a target in epilepsy. Yet, selective BGT1 inhibitors are needed for validation of this hypothesis. In that search, a series of BGT1 inhibitors typified by (1R,2S)-2-((4,4-bis(3-methylthiophen-2-yl)but-3-en-yl)(methyl)amino)cyclohexanecarboxylic acid (SBV2-114) was developed. A thorough pharmacological characterization of SBV2-114 using a cell-based [3H]GABA uptake assay at heterologously expressed BGT1, revealed an elusive biphasic inhibition profile with two IC50 values (4.7 and 556 μM). The biphasic profile was common for this structural class of compounds, including EF1502, and was confirmed in the MDCK II cell line endogenously expressing BGT1. The possibility of two binding sites for SBV2-114 at BGT1 was assessed by computational docking studies and examined by mutational studies. These investigations confirmed that the conserved residue Q299 in BGT1 is involved in, but not solely responsible for the biphasic inhibition profile of SBV2-114. Animal studies revealed anti-seizure effects of SBV2-114 in two mouse models, supporting a function of BGT1 in epilepsy. However, as SBV2-114 is apparent to be rather non-selective for BGT1, the translational relevance of this observation is unknown. Nevertheless, SBV2-114 constitutes a valuable tool compound to study the molecular mechanism of an emerging biphasic profile of BGT1-mediated GABA transport and the putative involvement of two binding sites for this class of compounds.
AuthorsMaria E K Lie, Stefanie Kickinger, Jonas Skovgaard-Petersen, Gerhard F Ecker, Rasmus P Clausen, Arne Schousboe, H Steve White, Petrine Wellendorph
JournalNeurochemical research (Neurochem Res) Vol. 45 Issue 7 Pg. 1551-1565 (Jul 2020) ISSN: 1573-6903 [Electronic] United States
PMID32248400 (Publication Type: Journal Article)
Chemical References
  • Anticonvulsants
  • GABA Plasma Membrane Transport Proteins
  • Slc6a12 protein, mouse
Topics
  • Acoustic Stimulation (adverse effects)
  • Animals
  • Anticonvulsants (pharmacology, therapeutic use)
  • CHO Cells
  • Cricetulus
  • Epilepsy, Reflex (drug therapy, metabolism)
  • GABA Plasma Membrane Transport Proteins (chemistry, metabolism)
  • HEK293 Cells
  • Humans
  • Male
  • Mice
  • Mice, Transgenic
  • Protein Binding (physiology)
  • Protein Structure, Secondary
  • Seizures (drug therapy, etiology, metabolism)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: